{"nctId":"NCT01297465","briefTitle":"PERgoveriS In Stratified Treatment for Assisted Reproductive Technique","startDateStruct":{"date":"2011-05-31","type":"ACTUAL"},"conditions":["Assisted Reproductive Techniques","Reproductive Technology, Assisted"],"count":202,"armGroups":[{"label":"Gonal-f® Plus Pergoveris®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Gonal-f®","Drug: Pergoveris®","Drug: Recombinant human chorionic gonadotropin (r-hCG)"]},{"label":"Pergoveris®","type":"EXPERIMENTAL","interventionNames":["Drug: Pergoveris®","Drug: Recombinant human chorionic gonadotropin (r-hCG)"]}],"interventions":[{"name":"Gonal-f®","otherNames":["Follitropin alfa"]},{"name":"Pergoveris®","otherNames":[]},{"name":"Pergoveris®","otherNames":[]},{"name":"Recombinant human chorionic gonadotropin (r-hCG)","otherNames":["Ovidrel®","Ovitrelle®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be a female subject justifying an in vitro fertilization and embryo transfer (IVF/ET) treatment\n* Be between her 36th and 40th birthday (both included) at the time of the randomization visit\n* Have early follicular phase (Day 2-4) serum level of basal follicle stimulating hormone (FSH less than or equal to (=\\<)12 IU/L) measured in the center's local laboratory during the screening period (that is within 2 months prior to down-regulation start)\n* A body mass index (BMI) less than (\\<) 30 kilogram per square meter (kg/m\\^2)\n* Have a regular spontaneous ovulatory menstrual cycle between 21 and 35 days in length\n* Be willing and able to comply with the protocol for the duration of the trial\n* Have given written informed consent, prior to any trial-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care\n* Have a male partner with semen analysis within the past 6 months prior to randomization considered adequate to proceed with regular insemination or intracytoplasmic sperm injection (ICSI) according to the center's standard practice. If these criteria are not met, the subject can only be entered if donor sperm will be used\n* Other protocol specified inclusion criteria could also apply.\n\nExclusion Criteria:\n\n* Had \\>= 2 previous ART cycles with a poor response to gonadotrophin stimulation defined as =\\< 6 mature follicles and/or =\\<4 oocytes collected in any previous IVF cycle or previous cycles with a hyper response defined as \\>= 25 oocytes retrieved\n* Any medical condition, which in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug. In case of doubt, the subject in question should be discussed with Merck Serono's medical responsible\n* Had previous severe ovarian Hyperstimulation Syndrome (OHSS)\n* Polycystic ovary syndrome (PCOS; Rotterdam criteria) to reduce the risk of the occurrence of OHSS\n* Any contraindication to being pregnant and/or carrying a pregnancy to term\n* History of 3 or more miscarriages (early or late miscarriages) due to any cause\n* A clinically significant systemic disease\n* Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus in the trial subject or her male partner\n* Known allergy or hypersensitivity to human gonadotrophin preparations\n* Entered previously into this trial or simultaneous participation in another clinical trial.\n* Pregnancy and lactation period\n* Participation in another clinical trial within the past 30 days\n* Other protocol specified inclusion criteria could also apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"36 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Number of Oocytes Retrieved","description":"The total number of oocytes retrieved per reporting group on the day of ovum pick-up (OPU) (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"6.5"},{"groupId":"OG001","value":"9.7","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Total Dose and Mean Daily Dose of Follicle Stimulating Hormone (FSH)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3292","spread":"851"},{"groupId":"OG001","value":"3321","spread":"850"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"307","spread":"43"},{"groupId":"OG001","value":"311","spread":"41"}]}]}]},{"type":"SECONDARY","title":"Total Number of Stimulation Treatment Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"1.6"},{"groupId":"OG001","value":"10.6","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Implantation Rate","description":"Implantation rate per reporting group was measured as the number of fetal sacs observed, divided by the number of embryos transferred multiplied by 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"29.1"},{"groupId":"OG001","value":"24.7","spread":"36.1"}]}]}]},{"type":"SECONDARY","title":"Number of Fetal Sacs With Activity","description":"Number of fetal sacs with activity was evaluated by ultrasound scan","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.5"},{"groupId":"OG001","value":"1.2","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Number of Fetal Hearts With Activity","description":"Number of fetal hearts with activity was evaluated by ultrasound scan","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.5"},{"groupId":"OG001","value":"1.3","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Clinical Pregnancy Rate","description":"Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy. Clinical pregnancy rate was reported as total clinical pregnancy rate, clinical pregnancy rate per cycle started and per embryo transfer \\[ET\\]).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":null},{"groupId":"OG001","value":"34.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Cancelled Cycles Due to Excessive or Insufficient Ovarian Response to Treatment","description":"An excessive ovarian response: greater than or equal to 25 oocytes which could put the participant at risk of OHSS; An insufficient ovarian response: defined as 3 or less follicles of greater than or equal to 12 millimeter developing following at least 7 days of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Biochemical Pregnancies Rate","description":"Biochemical pregnancy was defined as the pregnancy diagnosed only by the detection of human chorionic gonadotropin (hCG) in serum or urine and that does not develop into a clinical pregnancy. Participants with beta- hCG concentration greater than 10 international units per liter (IU/L) were considered as biochemical pregnant.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Multiple Pregnancies","description":"Multiple pregnancy was defined as the existence of more than one fetal sac with fetal heart activity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Early and Late Ovarian Hyper Stimulation Syndrome (OHSS)","description":"Ovarian Hyper Stimulation Syndrome (OHSS) is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting. Early OHSS was defined as the onset of OHSS occurring within 9 days after oocyte retrieval and late OHSS was defined as the onset of OHSS occurring on or after day 10 from oocyte retrieval.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events","description":"An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Systolic and Diastolic Arterial Blood Pressure Assessments","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118.9","spread":"12.8"},{"groupId":"OG001","value":"121.2","spread":"14.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":"9.8"},{"groupId":"OG001","value":"76.8","spread":"9.5"}]}]}]},{"type":"SECONDARY","title":"Heart Rate Assessments","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":"10.5"},{"groupId":"OG001","value":"76.5","spread":"10"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":99},"commonTop":["Headache","Abdominal pain","Nasopharyngitis","Ovarian hyperstimulation syndrome","Vaginal haemorrhage"]}}}